GP, KM: Conceptualization, Investigation, Writing—original draft, Writing—review & editing. LM: Writing—review & editing. AS: Validation, Writing—review & editing, Supervision. All authors have read and approved the submitted version.
Conflicts of interest
Anastasios Stathis: research grants (institutional): Astra Zeneca, Bayer, Eli Lilly, Incyte, Janssen, Roche, Abbvie, ADC Therapeutics, Amgen, Merck MSD, Novartis, Pfizer, Philogen, and Cellestina; travel grants: Astra Zeneca, Incyte; expert testimony (institutional): Bayer, Eli Lilly; advisory board (institutional): Roche, Jannsen. Anastasios Stathis, who is the Guest Editor of Exploration of Targeted Anti-tumor Therapy, had no involvement in the decision-making or the review process of this manuscript. All the other authors declare that they have no conflicts of interest.
Joubert N, Beck A, Dumontet C, Denevault-Sabourin C. Antibody–drug conjugates: the last decade.Pharmaceuticals (Basel). 2020;13:245. [DOI] [PubMed] [PMC]
Drago JZ, Modi S, Chandarlapaty S. Unlocking the potential of antibody–drug conjugates for cancer therapy.Nat Rev Clin Oncol. 2021;18:327–44. [DOI] [PubMed] [PMC]
García-Alonso S, Ocaña A, Pandiella A. Resistance to antibody–drug conjugates.Cancer Res. 2018;78:2159–65. [DOI] [PubMed]
Díaz-Rodríguez E, Gandullo-Sánchez L, Ocaña A, Pandiella A. Novel ADCs and strategies to overcome resistance to anti-HER2 ADCs.Cancers (Basel). 2021;14:154. [DOI] [PubMed] [PMC]
Coats S, Williams M, Kebble B, Dixit R, Tseng L, Yao NS, et al. Antibody–drug conjugates: future directions in clinical and translational strategies to improve the therapeutic index.Clin Cancer Res. 2019;25:5441–8. [DOI] [PubMed]
Fuentes-Antrás J, Genta S, Vijenthira A, Siu LL. Antibody–drug conjugates: in search of partners of choice.Trends Cancer. 2023;9:339–54. [DOI] [PubMed]
Moskowitz CH, Walewski J, Nademanee A, Masszi T, Agura E, Holowiecki J, et al. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse.Blood. 2018;132:2639–42. [DOI] [PubMed]
Horwitz SM, Scarisbrick JJ, Dummer R, Whittaker S, Duvic M, Kim YH, et al. Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician’s choice in cutaneous T-cell lymphoma: final data.Blood Adv. 2021;5:5098–106. [DOI] [PubMed] [PMC]
Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma.J Clin Oncol. 2012;30:2183–9. [DOI] [PubMed] [PMC]
Deeks ED. Polatuzumab vedotin: first global approval.Drugs. 2019;79:1467–75. [DOI] [PubMed] [PMC]
Powles TB, Perez Valderrama B, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, et al. LBA6 EV-302/KEYNOTE-A39: open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC).Ann Oncol. 2023;34:S1340. [DOI]
Bross PF, Beitz J, Chen G, Chen XH, Duffy E, Kieffer L, et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.Clin Cancer Res. 2001;7:1490–6. [PubMed]
Taksin AL, Legrand O, Raffoux E, de Revel T, Thomas X, Contentin N, et al. High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group.Leukemia. 2007;21:66–71. [DOI] [PubMed]
Petersdorf SH, Kopecky KJ, Slovak M, Willman C, Nevill T, Brandwein J, et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia.Blood. 2013;121:4854–60. [DOI] [PubMed] [PMC]
Castaigne S, Pautas C, Terré C, Raffoux E, Bordessoule D, Bastie JN, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study.Lancet. 2012;379:1508–16. [DOI] [PubMed]
Amadori S, Suciu S, Selleslag D, Stasi R, Alimena G, Baila L, et al. Randomized trial of two schedules of low-dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and GIMEMA leukaemia groups (AML-19).Br J Haematol. 2010;149:376–82. [DOI] [PubMed] [PMC]
Gamis AS, Alonzo TA, Meshinchi S, Sung L, Gerbing RB, Raimondi SC, et al. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531.J Clin Oncol. 2014;32:3021–32. [DOI] [PubMed] [PMC]
Debureaux PE, Labopin M, Mamez AC, Lapusan S, Isnard F, Adaeva R, et al. Fractionated gemtuzumab ozogamicin in association with high dose chemotherapy: a bridge to allogeneic stem cell transplantation in refractory and relapsed acute myeloid leukemia.Bone Marrow Transplant. 2020;55:452–60. [DOI] [PubMed]
Hütter-Krönke ML, Benner A, Döhner K, Krauter J, Weber D, Moessner M, et al. Salvage therapy with high-dose cytarabine and mitoxantrone in combination with all-trans retinoic acid and gemtuzumab ozogamicin in acute myeloid leukemia refractory to first induction therapy.Haematologica. 2016;101:839–45. [DOI] [PubMed] [PMC]
Scott LJ. Brentuximab vedotin: a review in CD30-positive hodgkin lymphoma.Drugs. 2017;77:435–45. [DOI] [PubMed] [PMC]
Younes A, Connors JM, Park SI, Fanale M, O’Meara MM, Hunder NN, et al. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin’s lymphoma: a phase 1, open-label, dose-escalation study.Lancet Oncol. 2013;14:1348–56. [DOI] [PubMed]
Straus DJ, Długosz-Danecka M, Connors JM, Alekseev S, Illés Á, Picardi M, et al. Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial.Lancet Haematol. 2021;8:e410–21. [DOI] [PubMed]
Ansell SM, Radford J, Connors JM, Długosz-Danecka M, Kim WS, Gallamini A, et al. Overall survival with brentuximab vedotin in stage III or IV Hodgkin’s Lymphoma.N Engl J Med. 2022;387:310–20. [DOI] [PubMed]
Milunović V, Mišura Jakobac K, Kursar M, Mandac Rogulj I, Ostojić Kolonić S. FDA’s and EMA’s approval of brentuximab vedotin for advanced Hodgkin lymphoma: another player in the town?Eur J Haematol. 2019;103:145–51. [DOI] [PubMed]
Horwitz S, O’Connor OA, Pro B, Illidge T, Fanale M, Advani R, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.Lancet. 2019;393:229–40. [DOI] [PubMed] [PMC]
Horwitz S, O'Connor OA, Pro B, Trümper L, Iyer S, Advani R, et al. The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma.Ann Oncol. 2022;33:288–98. [DOI] [PubMed] [PMC]
Castellino SM, Pei Q, Parsons SK, Hodgson D, McCarten K, Horton T, et al. Brentuximab vedotin with chemotherapy in pediatric high-risk Hodgkin’s lymphoma.N Engl J Med. 2022;387:1649–60. [DOI] [PubMed] [PMC]
Borchmann P, Moccia AA, Greil R, Schneider G, Hertzberg M, Schaub V, et al. Brecadd is non-inferior to ebeacopp in patients with advanced stage classical Hodgkin lymphoma: efficacy results of the GHSG phase III HD21 trial.Hematol Oncol. 2023;41(S2):881–2. [DOI]
Sehn LH, Herrera AF, Flowers CR, Kamdar MK, McMillan A, Hertzberg M, et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma.J Clin Oncol. 2020;38(2):155–65. [DOI] [PubMed] [PMC]
Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trněný M, Sharman JP, et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma.N Engl J Med. 2022;386:351–63. [DOI] [PubMed]
Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia.N Engl J Med. 2016;375:740–53. [DOI] [PubMed] [PMC]
Kantarjian H, Haddad FG, Jain N, Sasaki K, Short NJ, Loghavi S, et al. Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia.J Hematol Oncol. 2023;16:44. [DOI] [PubMed] [PMC]
Jabbour E, Short NJ, Senapati J, Jain N, Huang X, Daver N, et al. Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial.Lancet Haematol. 2023;10:e433–44. [DOI] [PubMed]
Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody–cytotoxic drug conjugate.Cancer Res. 2008;68:9280–90. [DOI] [PubMed]
Amiri-Kordestani L, Blumenthal GM, Xu QC, Zhang L, Tang SW, Ha L, et al. FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer.Clin Cancer Res. 2014;20:4436–41. [DOI] [PubMed]
Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram M, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer.N Engl J Med. 2012;367:1783–91. [DOI] [PubMed] [PMC]
von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer.N Engl J Med. 2019;380:617–28. [DOI] [PubMed]
Thuss-Patience PC, Shah MA, Ohtsu A, Van Cutsem E, Ajani JA, Castro H, et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study.Lancet Oncol. 2017;18:640–53. [DOI] [PubMed]
Li BT, Shen R, Buonocore D, Olah ZT, Ni A, Ginsberg MS, et al. Ado-trastuzumab emtansine for patients with HER2-mutant lung cancers: results from a phase II basket trial.J Clin Oncol. 2018;36:2532–7. [DOI] [PubMed] [PMC]
Cortés J, Diéras V, Lorenzen S, Montemurro F, Riera-Knorrenschild J, Thuss-Patience P, et al. Efficacy and safety of trastuzumab emtansine plus capecitabine vs trastuzumab emtansine alone in patients with previously treated ERBB2 (HER2)-positive metastatic breast cancer: a phase 1 and randomized phase 2 trial.JAMA Oncol. 2020;6:1203–9. [DOI] [PubMed] [PMC]
Martin M, Fumoleau P, Dewar JA, Albanell J, Limentani SA, Campone M, et al. Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study.Ann Oncol. 2016;27:1249–56. [DOI] [PubMed]
Krop IE, Modi S, LoRusso PM, Pegram M, Guardino E, Althaus B, et al. Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer.Breast Cancer Res. 2016;18:34. [DOI] [PubMed] [PMC]
Kan S, Koido S, Okamoto M, Hayashi K, Ito M, Kamata Y, et al. Up-regulation of HER2 by gemcitabine enhances the antitumor effect of combined gemcitabine and trastuzumab emtansine treatment on pancreatic ductal adenocarcinoma cells.BMC Cancer. 2015;15:726. [DOI] [PubMed] [PMC]
Kan S, Koido S, Okamoto M, Hayashi K, Ito M, Kamata Y, et al. Gemcitabine treatment enhances HER2 expression in low HER2-expressing breast cancer cells and enhances the antitumor effects of trastuzumab emtansine.Oncol Rep. 2015;34:504–10. [DOI] [PubMed]
Nakada T, Sugihara K, Jikoh T, Abe Y, Agatsuma T. The latest research and development into the antibody–drug conjugate, [fam-] trastuzumab deruxtecan (DS-8201a), for HER2 cancer therapy.Chem Pharm Bull (Tokyo). 2019;67:173–85. [DOI] [PubMed]
Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer.N Engl J Med. 2020;382:610–21. [DOI] [PubMed] [PMC]
Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, et al. Trastuzumab deruxtecan in previously treated HER2-Low advanced breast cancer.N Engl J Med. 2022;387:9–20. [DOI] [PubMed] [PMC]
Shitara K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer.N Engl J Med. 2020;382:2419–30. [DOI] [PubMed]
Goto K, Goto Y, Kubo T, Ninomiya K, Kim SW, Planchard D, et al. Trastuzumab deruxtecan in patients with HER2-mutant metastatic non–small-cell lung cancer: primary results from the randomized, phase II DESTINY-Lung02 trial.J Clin Oncol. 2023;41:4852–63. [DOI] [PubMed] [PMC]
Yoshino T, Di Bartolomeo M, Raghav K, Masuishi T, Loupakis F, Kawakami H, et al. Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer.Nat Commun. 2023;14:3332. [DOI] [PubMed] [PMC]
Meric-Bernstam F, Makker V, Oaknin A, Oh DY, Banerjee S, González-Martín A, et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 Phase II Trial.J Clin Oncol. 2024;42:47–58. [DOI] [PubMed] [PMC]
Andre F, Hamilton EP, Loi S, Schmid P, Anders CK, Yu T, et al. Trastuzumab deruxtecan (T-DXd) combinations in patients with HER2-positive advanced or metastatic breast cancer: a phase 1b/2, open-label, multicenter, dose-finding and dose-expansion study (DESTINY-Breast07).J Clin Oncol. 2021;39:TPS1096. [DOI]
Andre F, Hamilton EP, Loi S, Im SA, Sohn J, Tseng LM, et al. Dose-finding and -expansion studies of trastuzumab deruxtecan in combination with other anti-cancer agents in patients (pts) with advanced/metastatic HER2+ (DESTINY-Breast07 [DB-07]) and HER2-low (DESTINY-Breast08 [DB-08]) breast cancer (BC).J Clin Oncol. 2022;40:3025. [DOI]
Janjigian YY, Oh DY, Rha SY, Lee KW, Steeghs N, Chao Y, et al. Dose-escalation and dose-expansion study of trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2+ gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03.J Clin Oncol. 2022;40:295. [DOI]
Ponte JF, Ab O, Lanieri L, Lee J, Coccia J, Bartle LM, et al. Mirvetuximab soravtansine (IMGN853), a folate receptor alpha–targeting antibody-drug conjugate, potentiates the activity of standard of care therapeutics in ovarian cancer models.Neoplasia. 2016;18:775–84. [DOI] [PubMed] [PMC]
Matulonis UA, Lorusso D, Oaknin A, Pignata S, Dean A, Denys H, et al. Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from the SORAYA study.J Clin Oncol. 2023;41:2436–45. [DOI] [PubMed] [PMC]
Moore KN, O’Malley DM, Vergote I, Martin LP, Gonzalez-Martin A, Malek K, et al. Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer.Gynecol Oncol. 2018;151:46–52. [DOI] [PubMed]
Golfier S, Kopitz C, Kahnert A, Heisler I, Schatz CA, Stelte-Ludwig B, et al. Anetumab ravtansine: a novel mesothelin-targeting antibody–drug conjugate cures tumors with heterogeneous target expression favored by bystander effect.Mol Cancer Ther. 2014;13:1537–48. [DOI] [PubMed]
Hassan R, Blumenschein GR Jr, Moore KN, Santin AD, Kindler HL, Nemunaitis JJ, et al. First-in-human, multicenter, phase I dose-escalation and expansion study of anti-mesothelin antibody–drug conjugate anetumab ravtansine in advanced or metastatic solid tumors.J Clin Oncol. 2020;38:1824–35. [DOI] [PubMed] [PMC]
Santin AD, Vergote I, González-Martín A, Moore K, Oaknin A, Romero I, et al. Safety and activity of anti-mesothelin antibody–drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study.Int J Gynecol Cancer. 2023;33:1–9. [DOI] [PubMed] [PMC]
Goss GD, Vokes EE, Gordon MS, Gandhi L, Papadopoulos KP, Rasco DW, et al. Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor.Cancer. 2018;124:2174–83. [DOI] [PubMed] [PMC]
Van Den Bent M, Eoli M, Sepulveda JM, Smits M, Walenkamp A, Frenel JS, et al. INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma.Neuro Oncol. 2020;22:684–93. [DOI] [PubMed] [PMC]
Padovan M, Eoli M, Pellerino A, Rizzato S, Caserta C, Simonelli M, et al. Depatuxizumab mafodotin (depatux-m) plus temozolomide in recurrent glioblastoma patients: real-world experience from a multicenter study of italian association of neuro-oncology (AINO).Cancers (Basel). 2021;13:2773. [DOI] [PubMed] [PMC]
Whiteman KR, Johnson HA, Mayo MF, Audette CA, Carrigan CN, LaBelle A, et al. Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft models.MAbs. 2014;6:556–66. [DOI] [PubMed] [PMC]
Socinski, M.A., et al. A., et al. Phase 1/2 study of the CD56-targeting antibody-drug conjugate lorvotuzumab mertansine (IMGN901) in combination with carboplatin/etoposide in small-cell lung cancer patients with extensive-stage disease.Clin Lung Cancer. 2017;18:68–76 e2. [DOI] [PubMed]
Nicolò E, Giugliano F, Ascione L, Tarantino P, Corti C, Tolaney SM, et al. Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives.Cancer Treat Rev. 2022;106:102395. [DOI] [PubMed]
Zinzani PL, Santoro A, Gritti G, Brice P, Barr PM, Kuruvilla J, et al. Nivolumab combined with brentuximab vedotin for relapsed/refractory primary mediastinal large B-Cell Lymphoma: efficacy and safety from the phase II CheckMate 436 study.J Clin Oncol. 2019;37:3081–9. [DOI] [PubMed] [PMC]
Diefenbach CS, Hong F, Ambinder RF, Cohen JB, Robertson MJ, David KA, et al. Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial.Lancet Haematol. 2020;7:e660–70. [DOI] [PubMed] [PMC]
Armand P, Engert A, Younes A, Fanale M, Santoro A, Zinzani PL, et al. Nivolumab for relapsed/refractory classic hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 Trial.J Clin Oncol. 2018;36:1428–39. [DOI] [PubMed] [PMC]
Massaro F, Meuleman N, Bron D, Vercruyssen M, Maerevoet M. Brentuximab vedotin and pembrolizumab combination in patients with relapsed/refractory Hodgkin lymphoma: a single-centre retrospective analysis.Cancers (Basel). 2022;14:982. [DOI] [PubMed] [PMC]
Cowey CL, Fiorillo JA, Larson T, Waterhouse DM, Chaney MF, Knowles S, et al. 1029TiP Phase II trial of pembrolizumab (pembro) and brentuximab vedotin (BV) in patients with metastatic solid malignancies after progression on prior programmed cell death protein (PD)-1 inhibitors (SGN35-033).Ann Oncol. 2021;32:S862. [DOI]
Müller P, Kreuzaler M, Khan T, Thommen DS, Martin K, Glatz K, et al. Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade.Sci Transl Med. 2015;7:315ra188. [DOI] [PubMed]
Emens LA, Esteva FJ, Beresford M, Saura C, De Laurentiis M, Kim SB, et al. Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial.Lancet Oncol. 2020;21:1283–95. [DOI] [PubMed]
Loi S, Schneeweiss A, Song E, Harries M, De Laurentiis M, Li Y, et al. 329TiP KATE3: A phase III study of trastuzumab emtansine (T-DM1) in combination with atezolizumab or placebo in patients with previously treated HER2-positive and PD-L1–positive locally advanced or metastatic breast cancer.Ann Oncol. 2021;32:S509. [DOI]
Hamilton EP, Kaklamani V, Falkson C, Vidal GA, Ward PJ, Patre M, et al. Impact of Anti-HER2 treatments combined with atezolizumab on the tumor immune microenvironment in early or metastatic breast cancer: results from a phase Ib study.Clin Breast Cancer. 2021;21:539–51. [DOI] [PubMed]
Waks AG, Keenan T, Li T, Tayob N, Wulf GM, Richardson ET, et al. A phase Ib study of pembrolizumab (pembro) plus trastuzumab emtansine (T-DM1) for metastatic HER2+ breast cancer (MBC).J Clin Oncol. 2020;38:1046. [DOI]
Waks AG, Keenan TE, Li T, Tayob N, Wulf GM, Richardson ET 3rd, et al. Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer.J Immunother Cancer. 2022;10:e005119. [DOI] [PubMed] [PMC]
Iwata TN, Ishii C, Ishida S, Ogitani Y, Wada T, Agatsuma T. A HER2-targeting antibody-drug conjugate, trastuzumab deruxtecan (DS-8201a), enhances antitumor immunity in a mouse model.Mol Cancer Ther. 2018;17:1494–503. [DOI] [PubMed]
Hamilton E, Shapiro CL, Petrylak D, Boni V, Martin M, Conte GD, et al. Abstract PD3-07: trastuzumab deruxtecan (T-DXd; DS-8201) with nivolumab in patients with HER2-expressing, advanced breast cancer: A 2-part, phase 1b, multicenter, open-label study.Cancer Res. 2021;81:PD3-07. [DOI]
Schmid P, Im SA, Armstrong A, Park YH, Chung WP, et al. BEGONIA: Phase 1b/2 study of durvalumab (D) combinations in locally advanced/metastatic triple-negative breast cancer (TNBC)—Initial results from arm 1, d+paclitaxel (P), and arm 6, d+trastuzumab deruxtecan (T-DXd).J Clin Oncol. 2021;39:1023. [DOI]
Borghaei H, Besse B, Bardia A, Mazieres J, Popat S, Augustine B, et al. Trastuzumab deruxtecan (T-DXd; DS-8201) in combination with pembrolizumab in patients with advanced/metastatic breast or non-small cell lung cancer (NSCLC): a phase Ib, multicenter, study.J Clin Oncol. 2020;38:TPS1100. [DOI]
Goldenberg DM, Cardillo TM, Govindan SV, Rossi EA, Sharkey RM. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC).Oncotarget. 2015;6:22496–512. [DOI] [PubMed] [PMC]
Pavone G, Motta L, Martorana F, Motta G, Vigneri P. A new kid on the block: sacituzumab govitecan for the treatment of breast cancer and other solid tumors.Molecules. 2021;26:7294. [DOI] [PubMed] [PMC]
Grivas P, Pouessel D, Park CH, Barthélémy P, Bupathi M, Petrylak PD. TROPHY-U-01 Cohort 3: sacituzumab govitecan (SG) in combination with pembrolizumab (Pembro) in patients (pts) with metastatic urothelial cancer (mUC) who progressed after platinum (PLT)-based regimens.J Clin Oncol. 2022;40:434. [DOI]
Jain RK, Yang Y, Chadha J, Chatwal SM, Kish JN, Raymond S, et al. Phase I/II study of ipilimumab plus nivolumab combined with sacituzumab govitecan in patients with metastatic cisplatin-ineligible urothelial carcinoma.J Clin Oncol. 2023;41:521. [DOI]
Coleman RL, Lorusso D, Gennigens C, González-Martín A, Randall L, Cibula D, et al. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study.Lancet Oncol. 2021;22:609–19. [DOI] [PubMed]
Vergote I, Nieuwenhuysen EV, O’Cearbhaill RE, Westermann A, Lorusso D, Ghamande S, et al. Tisotumab vedotin in combination with carboplatin, pembrolizumab, or bevacizumab in recurrent or metastatic cervical cancer: results from the innovaTV 205/GOG-3024/ENGOT-cx8 study.J Clin Oncol. 2023;41:5536–49. [DOI] [PubMed] [PMC]
Ab O, Whiteman KR, Bartle LM, Sun X, Singh R, Tavares D, et al. IMGN853, a folate receptor-α (FRα)–targeting antibody–drug conjugate, exhibits potent targeted antitumor activity against FRα-expressing tumors.Mol Cancer Ther. 2015;14:1605–13. [DOI] [PubMed]
Matulonis UA, Moore KN, Martin LP, Vergote IB, Castro C, Gilbert L, et al. Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), with pembrolizumab in platinum-resistant ovarian cancer (PROC): initial results of an expansion cohort from FORWARD II, a phase Ib study.Ann Oncol. 2018;29:VIII339. [DOI]
Kostic A, Anderson M, Duniho S, Miyamoto J, Nesterova A, Nesterova S. SGN-LIV1A, an antibody-drug conjugate (ADC), in patients with LIV-1–positive breast cancer.J Clin Oncol. 2014;32:TPS1143. [DOI]
Modi S, Pusztai L, Forero A, Mita M, Miller KD, Weise A, et al. Abstract PD3-14: phase 1 study of the antibody-drug conjugate SGN-LIV1A in patients with heavily pretreated triple-negative metastatic breast cancer.Cancer Res. 2018;78:PD3–14. [DOI]
Han HH, Diab S, Alemany C, Basho R, Brown-Glaberman U, Meisel J, et al. Abstract PD1-06: Open label phase 1b/2 study of ladiratuzumab vedotin in combination with pembrolizumab for first-line treatment of patients with unresectable locally-advanced or metastatic triple-negative breast cancer.Cancer Res. 2020;80:PD1–06. [DOI]
Shi F, Liu Y, Zhou X, Shen P, Xue R, Zhang M. Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy.Drug Deliv. 2022;29:1335–44. [DOI] [PubMed] [PMC]
Sheng X, Yan X, Wang L, Shi Y, Yao X, Luo H, et al. Open-label, Multicenter, phase II study of RC48-ADC, a HER2-targeting antibody–drug conjugate, in patients with locally advanced or metastatic urothelial carcinoma.Clin Cancer Res. 2021;27:43–51. [DOI] [PubMed]
Zhou L, Xu H, Li S, Yan X, Li J, Wu X, et al. Study RC48-C014: preliminary results of RC48-ADC combined with toripalimab in patients with locally advanced or metastatic urothelial carcinoma.J Clin Oncol. 2022;40:515. [DOI]
Chen H, Sheng X, Hu B, Yao X, Liu Z, Yao X, et al. Toripalimab (anti-PD-1) monotherapy as a second-line treatment for patients with metastatic urothelial carcinoma (POLARIS-03): two-year survival update and biomarker analysis.J Clin Oncol. 2022;40:4566. [DOI]
Wang Y, Gong J, Wang A, Wei J, Peng Z, Wang X, et al. Disitamab vedotin (RC48) plus toripalimab for HER2-expressing advanced gastric or gastroesophageal junction and other solid tumours: a multicentre, open label, dose escalation and expansion phase 1 trial.EClinicalMedicine. 2024;68:102415. [DOI] [PubMed] [PMC]
Mansfield AS, Yin JV, Bradbury P, Kwiatkowski D, Patel S, Bazhenova L, et al. OA02.04 Phase 1/2 Randomized Trial of Anetumab Ravtansine and Pembrolizumab Compared to Pembrolizumab for Pleural Mesothelioma - NCT03126630.J Thorac Oncol. 2023;18:S47. [DOI]
Spiliopoulou P, Kasi A, Abushahin LI, Cardin DB, Lenz HJ, Dayyaniet F, et al. Phase Ib study of anetumab ravtansive in combination with immunotherapy or immunotherapy plus chemotherapy in mesothelin-enriched advanced pancreatic adenocarcinoma: NCI10208.J Clin Oncol. 2022;40:4136. [DOI]
O’Connor BP, Raman VS, Erickson LD, Cook WJ, Weaver LK, Ahonen C, et al. BCMA is essential for the survival of long-lived bone marrow plasma cells.J Exp Med. 2004;199:91–8. [DOI] [PubMed] [PMC]
Lee L, Bounds D, Paterson J, Herledan G, Sully K, Seestaller-Wehr LM, et al. Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma.Br J Haematol. 2016;174:911–22. [DOI] [PubMed]
Tai YT, Mayes PA, Acharya C, Zhong MY, Cea M, Cagnetta A, et al. Novel anti–B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma.Blood. 2014;123:3128–38. [DOI] [PubMed] [PMC]
Lonial S, Lee HC, Badros A, Trudel S, Nooka AK, Chari A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.Lancet Oncol. 2020;21:207–21. [DOI] [PubMed]
Montes de Oca R, Alavi AS, Vitali N, Bhattacharya S, Blackwell C, Patel K, et al. Belantamab Mafodotin (GSK2857916) Drives Immunogenic Cell Death and Immune-mediated Antitumor Responses In Vivo.Mol Cancer Ther. 2021;20:1941–55. [DOI] [PubMed] [PMC]
Callander NS, Ribrag V, Richardson PG, Nooka AK, Song K, Uttervall K, et al. DREAMM-5 Study: Investigating the Synergetic Effects of Belantamab Mafodotin Plus Inducible T-Cell Co-Stimulator Agonist (aICOS) Combination Therapy in Patients with Relapsed/Refractory Multiple Myeloma.Blood. 2021;138:897. [DOI]
Suvannasankha A, Bahlis NJ, Trudel S, Weisel K, Koenecke C, Rocafiguera AO, et al. Safety and clinical activity of belantamab mafodotin with pembrolizumab in patients with relapsed/refractory multiple myeloma (RRMM): DREAMM-4 Study.J Clin Oncol. 2022;40:8018. [DOI]
Okajima D, Yasuda S, Maejima T, Karibe T, Sakurai K, Aida T, et al. Datopotamab Deruxtecan, a Novel TROP2-directed Antibody–drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells.Mol Cancer Ther. 2021;20:2329–40. [DOI] [PubMed] [PMC]
Krop I, Juric D, Shimizu T, Tolcher A, Spira A, Mukohara T, et al. Abstract GS1-05: Datopotamab deruxtecan in advanced/metastatic HER2- breast cancer: Results from the phase 1 TROPION-PanTumor01 study.Cancer Res. 2022;2:GS1–05. [DOI]
Levy B, Paz-Ares L, Rixe O, Su WC, Yang TY, Tolcher A, et al. MA13.07 TROPION-Lung02: Initial Results for Datopotamab Deruxtecan Plus Pembrolizumab and Platinum Chemotherapy in Advanced NSCLC.J Clin Oncol. 2022;17:S91. [DOI]
Schmid P, Wysocki PJ, Ma CX, Park YH, Fernandes R, Lord S, et al. 379MO Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Updated results from BEGONIA, a phase Ib/II study.Ann Oncol. 2023;4:S337. [DOI]
Bartlett NL, Yasenchak CA, Ashraf KK, Harwin WN, Orcutt JM, Kuriakose P, et al. Brentuximab vedotin in combination with lenalidomide and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: Safety and efficacy results from the safety run-in period of the phase 3 ECHELON-3 study.J Clin Oncol. 2022;40:7559. [DOI]
Kawasaki N, Nishito Y, Yoshimura Y, Yoshiura S. The molecular rationale for the combination of polatuzumab vedotin plus rituximab in diffuse large B-cell lymphoma.Br J Haematol. 2022;199:245–55. [DOI] [PubMed] [PMC]
Hutchings M, Sureda A, Terol MJ, Albareda FB, Corradini P, Larsen TS, et al. Glofitamab (Glofit) in Combination with Polatuzumab Vedotin (Pola): Phase Ib/II Preliminary Data Support Manageable Safety and Encouraging Efficacy in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL).Blood. 2021;138:525. [DOI]
Morschhauser F, Flinn IW, Advani R, Sehn LH, Diefenbach C, Kolibaba K, et al. Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS).Lancet Haematol. 2019;6:e254–65. [DOI] [PubMed]
Olszewski AJ, Budde LE, Chavez J, Ghosh N, Kamdar M, Lossos IS, et al. Mosunetuzumab with Polatuzumab Vedotin Is Effective and Has a Manageable Safety Profile in Patients Aged <65 and ≥65 Years with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) and ≥1 Prior Therapy: Subgroup Analysis of a Phase Ib/II Study.Blood. 2022;140:3757–9. [DOI]
Gritti G, Marlton P, Phillips TJ, Arthur C, Bannerji R, Corradini P, et al. Polatuzumab Vedotin Plus Venetoclax with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Primary Efficacy Analysis of a Phase Ib/II Study.Blood. 2020;136:45–7. [DOI]
Lasater EA, Amin DN, Bannerji R, Mali RS, Barrett K, Rys RN, et al. Targeting MCL-1 and BCL-2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non-Hodgkin lymphoma: Results from preclinical models and a Phase Ib study.Am J Hematol. 2023;98:449–63. [DOI] [PubMed]
Yuen S, Arthur C, Phillips T, Bannerji R, Isufi I, Gritti G, et al. polatuzumab vedotin (POLA) + obinutuzumab (G) + venetoclax (VEN) in patients (PTS) with relapsed/refractory (R/R) follicular lymphoma (FL): interim analysis of a phase IB/II TRIAL.EHA Library. 2020;293651:EP1162.
Bannerji R, Yuen S, Phillips TJ, Arthur C, Isufi I, Marlton PE, et al. Polatuzumab vedotin + obinutuzumab + venetoclax in patients with relapsed/refractory (R/R) follicular lymphoma (FL): primary analysis of a phase 1b/2 trial.J Clin Oncol. 2021;39:7534. [DOI]
Fayad L, Offner F, Smith MR, Verhoef G, Johnson P, Kaufman JL, et al. Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab.J Clin Oncol. 2013;31:573–83. [DOI] [PubMed] [PMC]
Dang NH, Ogura M, Castaigne S, Fayad L, Jerkeman M, Radford JA, et al. Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab (R-InO) versus chemotherapy for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (B-NHL).J Br J Haematol. 2018;32:8529. [DOI]
Pirosa MC, Zhang L, Hitz F, Novak U, Hess D, Terrot T, et al. A phase I trial of inotuzumab ozogamicin in combination with temsirolimus in patients with relapsed or refractory CD22-positive B-cell non-Hodgkin lymphomas.Leuk Lymphoma. 2022;63:117–23. [DOI] [PubMed]
Jain N, Maiti A, Ravandi F, Konopleva M, Daver N, Kadia T, et al. Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia.Am J Hematol. 2021;96:1000–7. [DOI] [PubMed] [PMC]
Caimi PF, Ai W, Alderuccio JP, Ardeshna KM, Hamadani M, Hess B, et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial.Lancet Oncol. 2021;22:790–800. [DOI] [PubMed]
Depaus J, Wagner-Johnston ND, Zinzani PL, Phillips TJ, Maly J, Ferrari S, et al. Interim results of loncastuximab tesirine combined with ibrutinib in diffuse large B-Cell lymphoma or mantle cell lymphoma (LOTIS-3). 62nd ASH Annual Meeting and Exposition Virtual Meeting. 2020 Dec 5-18. Washington: ASH; 2020.
Krop IE, Im SA, Barrios C, Bonnefoi H, Gralow J, Toi M, et al. Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer: The Phase III KAITLIN Study.J Clin Oncol. 2022;40:438–48. [DOI] [PubMed] [PMC]
Perez EA, Barrios C, Eiermann W, Toi M, Im YH, Conte P, et al. Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2–positive advanced breast cancer: Final results from MARIANNE.Cancer. 2019;125:3974–84. [DOI] [PubMed]
Hurvitz SA, Martin M, Jung KH, Huang CS, Harbeck N, Valero V, et al. Neoadjuvant trastuzumab emtansine and pertuzumab in human epidermal growth factor receptor 2–positive breast cancer: three-year outcomes from the phase III KRISTINE study.J Clin Oncol. 2019;37:2206–16. [DOI] [PubMed] [PMC]
Patel TA, Ensor JE, Creamer SL, Boone T, Rodriguez AA, Niravath PA, et al. A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study).Breast Cancer Res. 2019;21:100. [DOI] [PubMed] [PMC]
Lavaud P, Andre F. Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials.BMC Med. 2014;12:132. [DOI] [PubMed] [PMC]
Abraham J, Montero AJ, Jankowitz RC, Salkeni MA, Beumer JH, Kiesel BF, et al. Safety and efficacy of T-DM1 plus neratinib in patients with metastatic HER2-positive breast cancer: NSABP foundation trial FB-10.J Clin Oncol. 2019;37:2601–9. [DOI] [PubMed] [PMC]
Spring LM, Clark SL, Li T, Goel S, Tayob N, Viscosi E, et al. Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer.NPJ Breast Cancer. 2021;7:103. [DOI] [PubMed] [PMC]
Jain S, Shah AN, Santa-Maria CA, Siziopikou K, Rademaker A, Helenowski I, et al. Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy.Breast Cancer Res Treat. 2018;171:371–81. [DOI] [PubMed]
Sartore-Bianchi A, Lonardi S, Martino C, Fenocchio E, Tosi F, Ghezzi S, et al. Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial.ESMO Open. 2020;5:e000911. [DOI] [PubMed] [PMC]
Jebbink M, de Langen AJ, Monkhorst K, Boelens MC, van den Broek D, van der Noort V, et al. Trastuzumab-emtansine and osimertinib combination therapy to target HER2 bypass track resistance in EGFR mutation-positive NSCLC.JTO Clin Res Rep. 2023;4:100481. [DOI] [PubMed] [PMC]
McGregor BA, Sonpavde GP, Kwak L, Regan MM, Gao X, Hvidsten H, et al. The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma.Ann Oncol. 2024;35:91–7. [DOI] [PubMed]
Cardillo TM, Sharkey RM, Rossi DL, Arrojo R, Mostafa AA, Goldenberg DM. Synthetic lethality exploitation by Anti–Trop-2-SN-38 Antibody–Drug conjugate, IMMU-132, plus PARP inhibitors in BRCA1/2-wild-type triple-negative breast cancer.Clin Cancer Res. 2017;23:3405–15. [DOI] [PubMed]
Yap TA, Hamilton E, Bauer T, Dumbrava EE, Jeselsohn R, Enke A, et al. Phase Ib SEASTAR study: combining rucaparib and sacituzumab govitecan in patients with cancer with or without mutations in homologous recombination repair genes.JCO Precis Oncol. 2022;6:e2100456. [DOI] [PMC]
Bardia1 A, Spring LM, Juric D, Partridge A, Ligibel J, Kuter I, et al. 358TiP Phase Ib/II study of antibody-drug conjugate, sacituzumab govitecan, in combination with the PARP inhibitor, talazoparib, in metastatic triple-negative breast cancer.Ann Oncol. 2020:31:S394. [DOI]
Gorecki L, Andrs M, Rezacova M, Korabecny J. Discovery of ATR kinase inhibitor berzosertib (VX-970, M6620): clinical candidate for cancer therapy.Pharmacol Ther. 2020;210:107518. [DOI] [PubMed]
Abel ML, Takahashi N, Desai P, Peer C, Redon C, Nichols S, et al. Abstract CT268: Targeting replication stress and chemotherapy resistance with a combination of sacituzumab govitecan and berzosertib: a phase I clinical trial.Cancer Res. 2023;83:CT268. [DOI] [PubMed] [PMC]
Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy.Science. 2005;307:58–62. [DOI] [PubMed]
Gilbert L, Oaknin A, Matulonis UA, Mantia-Smaldone GM, Lim PC, Castro CM, et al. Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.Gynecol Oncol. 2023;170:241–7. [DOI] [PubMed]
Terpos E, Gavriatopoulou M, Ntanasis-Stathopoulos I, Malandrakis P, Fotiou D, Migkou M, et al. Safety and clinical activity of belantamab mafodotin plus lenalidomide and dexamethasone in transplant ineligible patients with newly diagnosed multiple myeloma: The phase 1/2, prospective, open-label, BelaRd study.J Clin Oncol. 2023;41:8050. [DOI]
Quach H, Gironell M, Lee C, Popat R, Cannell P, Kasinathan R, et al. Safety and clinical activity of belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM): DREAMM-6 arm-A interim analysis.J Clin Oncol. 2022;40:8017. [DOI]
Lheureux S, Alqaisi H, Cohn DE, Chern JY, Duska LR, Jewell A, et al. A randomized phase II study of bevacizumab and weekly anetumab ravtansine or weekly paclitaxel in platinum-resistant or refractory ovarian cancer NCI trial#10150.J Clin Oncol. 2022;40:5514. [DOI]
Jänne PA, Baik C, Su WC, Johnson ML, Hayashi H, Nishio M, et al. Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR-Mutated Non–Small Cell Lung Cancer.Cancer Discov. 2022;12:74–89. [DOI] [PubMed] [PMC]
Yonesaka K, Tanizaki J, Maenishi O, Haratani K, Kawakami H, Tanaka K, et al. HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cance.Clin Cancer Res. 2022;28:390–403. [DOI] [PubMed]
Blanc V, Bousseau A, Caron A, Carrez C, Lutz RJ, Lambert JM. SAR3419: an anti-CD19-maytansinoid immunoconjugate for the treatment of B-cell malignancies.Clin Cancer Res. 2011;17:6448–58. [DOI] [PubMed]
Trnĕný M, Verhoef G, Dyer MJ, Ben Yehuda D, Patti C, Canales M, et al. A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy.Haematologica. 2018;103:1351–8. [DOI] [PubMed] [PMC]
Coiffier B, Thieblemont C, de Guibert S, Dupuis J, Ribrag V, Bouabdallah R, et al. A phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma.Br J Haematol. 2016;173:722–30. [DOI]
Dhillon S. Moxetumomab pasudotox: first global approval.Drugs. 2018;78:1763–7. [DOI] [PubMed] [PMC]
Makawita S, Meric-Bernstam F. Antibody-drug conjugates: patient and treatment selection.Am Soc Clin Oncol Educ Book. 2020;40:105–14. [DOI] [PubMed]
Tarantino P, Carmagnani Pestana R, Corti C, Modi S, Bardia A, Tolaney SM, et al. Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies.CA Cancer J Clin. 2022;72:165–82. [DOI] [PubMed]
Zhuang W, Zhang W, Wang L, Xie L, Feng J, Zhang B, et al. Generation of a novel SORT1×HER2 bispecific antibody-drug conjugate targeting HER2-low-expression tumor.Int J Mol Sci. 2023;24:16056. [DOI] [PubMed] [PMC]
Perez Bay AE, Faulkner D, DaSilva JO, Young TM, Yang K, Giurleo JT, et al. A bispecific METxMET antibody–drug conjugate with cleavable linker is processed in recycling and late endosomes.Mol Cancer Ther. 2023;22:357–70. [DOI] [PubMed] [PMC]
Choi J, Jang H, Choi J, Choi Y, Yang Y, Shim MK, et al. Immune checkpoint-targeted drug conjugates: a promising tool for remodeling tumor immune microenvironment.J Control Release. 2023;359:85–96. [DOI] [PubMed]
